Does Quartz Health Solutions Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Complexity Arise?

Vyvanse is a central nervous system stimulant approved by the FDA in 2007 for ADHD in children age 6 and older, expanded to adults in 2008, and approved for moderate-to-severe binge-eating disorder (BED) in adults in 2015 [1]. Its active moiety is d-amphetamine, released after the prodrug lisdexamfetamine is cleaved by intestinal enzymes. Because it is a Schedule II controlled substance under the Controlled Substances Act, prescribing and dispensing rules are stricter than for most non-controlled medications [2].

That scheduling status is one reason insurers add extra utilization-management steps. Quartz Health Solutions, a Wisconsin-based nonprofit health plan serving Wisconsin, Minnesota, and Illinois members, treats Vyvanse the same way most regional Blue Cross or Medicaid managed-care organizations do: the drug sits on a higher formulary tier, carries prior authorization requirements, and in some plan designs triggers a step-therapy protocol before coverage kicks in.

The FDA approved the first generic lisdexamfetamine dimesylate capsules in 2023, which materially changed the cost picture [3]. Even if your Quartz plan places branded Vyvanse on Tier 4, the generic may sit on Tier 2 or Tier 3 at a noticeably lower copay. Asking your pharmacist to fill with the generic is now a practical option for most patients.

Stimulant medications like lisdexamfetamine carry a real-world effectiveness record. A 2018 meta-analysis published in The Lancet Psychiatry covering 133 double-blind randomized controlled trials (N = 10,068 children and adolescents; N = 8,131 adults) ranked lisdexamfetamine as the most effective medication for ADHD in adults by standardized mean difference (SMD 0.79 to 95% CI 0.64 to 0.93) [4]. That clinical data matters when building a prior authorization case with Quartz.

How Quartz Formularies Are Structured

Quartz uses a multi-tier formulary system across its commercial, marketplace (ACA), and Medicaid product lines. Each tier carries a different cost-sharing level.

Tier 1 covers generic preferred drugs at the lowest copay, usually $5 to $15 per 30-day fill. Tier 2 covers generic non-preferred or preferred brand drugs, often $30 to $60. Tier 3 covers brand preferred drugs, typically $60 to $120. Tier 4 covers brand non-preferred, commonly $100 to $200 or a percentage-based coinsurance. Specialty tiers (Tier 5) apply to high-cost biologics and are usually 25% to 33% coinsurance.

Branded Vyvanse has historically landed on Tier 3 or Tier 4 on most Quartz commercial plans. After the generic entry in 2023, generic lisdexamfetamine moved to Tier 2 on several Quartz plan designs, bringing it within a cost range that many patients find manageable.

The specific tier for your plan year depends on the plan you selected during open enrollment. Quartz publishes a drug lookup tool at its member portal, and the most current formulary PDFs are available there. Formularies change annually, so what was Tier 3 in a prior plan year may now be Tier 2, or vice versa. Always confirm the current tier before assuming your cost from a prior year still applies.

The HealthRX Quartz-Vyvanse Coverage Check Framework

Use this four-step sequence before your prescriber submits a prior authorization:

1. Log in to the Quartz member portal, run the drug formulary lookup for "lisdexamfetamine" and "Vyvanse" separately, and screenshot the tier and PA requirements for your specific plan.
2. Ask your prescriber's office to pull your "formulary exception and PA criteria" document from Quartz's provider portal. This lists exactly what clinical evidence Quartz requires for approval.
3. Confirm whether your plan includes step therapy. If so, identify which generic amphetamine is listed as the required first-step drug and for how long you must trial it (usually 30 days).
4. If step therapy is not clinically appropriate (e.g., prior failure, contraindication, or BED diagnosis where no step drug is specified), have your prescriber document that explicitly in the PA request.

Prior Authorization: What Quartz Typically Requires

Prior authorization (PA) is the single biggest obstacle most Quartz members face with Vyvanse. The PA process requires your prescribing clinician to submit clinical documentation showing medical necessity before Quartz will pay.

For ADHD indications, Quartz's standard PA criteria for brand-name stimulants generally require a documented ADHD diagnosis meeting DSM-5 criteria, patient age within the FDA-approved range (6 years and older for ADHD), and in many commercial plans evidence that a generic amphetamine or methylphenidate formulation was tried first. The American Academy of Pediatrics' 2019 clinical practice guideline, which covers ADHD evaluation and treatment through age 26, recommends medication as first-line treatment for children age 6 and older, and that guideline language is routinely cited in PA letters [5].

For BED indications, the criteria differ. Quartz typically requires documentation of a DSM-5 diagnosis of moderate-to-severe BED (8 or more binge-eating episodes per month), failure of or contraindication to an appropriate behavioral intervention, and in some plan designs a trial of topiramate or another agent listed as a step. The FDA approved Vyvanse specifically for BED in adults in January 2015, making it the only FDA-approved pharmacotherapy for that indication [1].

When a PA is approved, Quartz usually grants authorization for 12 months at a time, after which the prescriber must resubmit. Some pediatric ADHD authorizations are renewed with minimal documentation if records show ongoing treatment and no adverse events.

If the PA is denied, Quartz must send a written denial notice explaining the reason. Federal law under the ACA and CMS regulations requires health plans to process standard PA requests within 3 business days and urgent PA requests within 24 hours [6].

Step Therapy: The "Fail-First" Requirement Explained

Step therapy, sometimes called "fail-first," means Quartz will not cover Vyvanse until you have documented a trial of one or more lower-cost alternatives. Not all Quartz plans include step therapy for stimulants, but those that do typically require a 30-day trial of a generic mixed amphetamine salt (Adderall generic) or generic methylphenidate ER.

Several states where Quartz operates have passed "step therapy override" laws that require insurers to waive step therapy when a prescribing clinician documents a clinical reason why the step drug is contraindicated or previously failed. Wisconsin Act 26 (2017) established this right for Wisconsin-insured members. If your plan is governed by ERISA (most employer-sponsored plans), state law may not apply, but Quartz's internal exception process still exists.

A 2021 report from the Alliance for Patient Access found that step therapy delays in ADHD treatment are associated with missed school days, workplace productivity losses, and in some cases treatment dropout. Citing that kind of real-world burden in a PA override request can strengthen your clinician's case.

Your clinician should submit the override request in writing, with specific language: the patient "previously failed" the step drug (with dates and documented symptoms), or the step drug is "contraindicated" due to a comorbid condition or drug interaction, or the required step drug "is not an appropriate treatment" given the specific diagnosis.

Generic Lisdexamfetamine: A Coverage Shortcut in 2025

The FDA approved the first generic versions of lisdexamfetamine dimesylate capsules in 2023 [3]. By the 2024 and 2025 plan years, multiple generic manufacturers have entered the market, and Quartz has placed generic lisdexamfetamine on lower formulary tiers than the branded product on most plan designs.

This matters for three reasons. First, the generic carries the same therapeutic profile as branded Vyvanse. The FDA requires generic manufacturers to demonstrate bioequivalence within a 90% confidence interval of 80% to 125% for AUC and Cmax [7]. Second, if your plan requires step therapy with branded Vyvanse but generic lisdexamfetamine is now available, the step-therapy requirement may be satisfied by the generic at lower cost. Third, even if your prescriber has written "Vyvanse" on the prescription, your pharmacist can dispense the generic unless the script is marked "dispense as written" (DAW-1).

Talk to your Quartz-contracted pharmacy about substitution. Cash-pay prices for generic lisdexamfetamine at major chains dropped to approximately $100 to $160 per 30-day supply by late 2024 with GoodRx-type discount cards, well below the $380 to $430 branded list price.

What to Do If Quartz Denies Coverage

A denial is not a final answer. Federal and state law give you structured appeal rights.

Level 1: Internal Appeal. Submit a written appeal to Quartz within 180 days of the denial notice. Include a letter of medical necessity from your prescriber, relevant diagnostic documentation, any clinical trial data supporting Vyvanse over alternatives (the Lancet Psychiatry meta-analysis cited above is useful here [4]), and a statement of how the denial harms your health. Quartz must respond to a standard appeal within 30 days and an expedited appeal within 72 hours.

Level 2: External Independent Review. If Quartz upholds its denial, you may request an external independent review organization (IRO) review. IRO reviewers are board-certified physicians with no financial relationship to Quartz. Under ACA regulations, IRO decisions are binding on the insurer [6]. Wisconsin members can also file a complaint with the Wisconsin Office of the Commissioner of Insurance (OCI).

Level 3: State or Federal Complaint. ACA-compliant plans that repeatedly violate timely PA rules or fail to apply formulary exceptions correctly may be reported to the Wisconsin OCI or, for federally facilitated marketplace plans, to CMS.

A 2022 JAMA Internal Medicine analysis found that patients who appealed initial insurance denials for prescription medications won their appeal approximately 39% to 59% of the time, depending on the insurer and drug class. Persistence through the process matters.

Cost Assistance Options If Coverage Remains Incomplete

Even with Quartz coverage, out-of-pocket costs can be substantial. Several programs can reduce what you pay.

Takeda, the manufacturer of branded Vyvanse, has historically offered a savings card for commercially insured patients that reduced the copay to as low as $30 per 30-day fill. Eligibility and program availability change; confirm current terms at the Takeda patient support line or the official Vyvanse website. Note that savings cards typically cannot be used if your primary coverage is a government program (Medicare Part D, Medicaid, CHIP, TRICARE).

For patients on Medicaid through Quartz (ForwardHealth in Wisconsin), the federal Medicaid Drug Rebate Program may bring branded Vyvanse within coverage, though state preferred drug lists sometimes still require PA. Wisconsin ForwardHealth covers lisdexamfetamine for ADHD with PA.

The NeedyMeds database (needymeds.org) and the Partnership for Prescription Assistance maintain lists of patient assistance programs for lisdexamfetamine that may cover costs for uninsured or underinsured patients.

If cost is the primary barrier and you are clinically appropriate for generic lisdexamfetamine, switching from branded Vyvanse to the generic through your Quartz plan is now the most direct path to lower cost without navigating manufacturer programs.

ADHD Diagnosis Rates and Medication Coverage: The Broader Context

Approximately 9.4% of U.S. children aged 2 to 17 years have received an ADHD diagnosis, according to 2016 National Survey of Children's Health data compiled by the CDC [8]. Among adults, the National Comorbidity Survey Replication estimated a 4.4% prevalence of adult ADHD in the United States [9]. Stimulant medications remain the most studied pharmacological treatment for both populations.

The American Academy of Child and Adolescent Psychiatry (AACAP) states in its 2007 practice parameter (updated 2009): "Stimulant medications are the most thoroughly studied class of medications used in child and adolescent psychiatry" [10]. That guideline consensus supports the medical necessity argument your prescriber will make to Quartz.

For BED specifically, a key Phase 3 program showed Vyvanse 50 mg and 70 mg produced significant reductions in binge-eating days per week compared to placebo across three identically designed trials. In the pooled analysis, Vyvanse 70 mg reduced binge-eating days by approximately 3.87 days per week versus 1.97 days for placebo (P<0.001) [11]. That data point anchors the BED medical necessity argument in a PA request.

Key Questions to Ask Quartz Customer Service Before Filling

Before your prescriber sends a prescription to the pharmacy, a single call or portal inquiry to Quartz member services can prevent a surprise bill. Have your insurance ID card ready and ask:

Is lisdexamfetamine or Vyvanse on my current formulary, and at which tier? Does my plan require prior authorization, and if so, what are the criteria? Does my plan require step therapy, and which drugs are listed as required first steps? Is there a quantity limit (most plans allow 30 capsules per 30-day supply)? Does my deductible need to be met before the copay applies?

Document the name of the representative, the date, and the reference number for each call. That record is useful if a pharmacy claim is later rejected for reasons that contradict what member services told you.

How a Prescriber Can Optimize the Prior Authorization Submission

A poorly constructed PA request is the most common reason Quartz denies Vyvanse on the first attempt. Prescribers who include the following elements in the initial submission see higher first-pass approval rates:

DSM-5 diagnostic criteria met, with specific symptom documentation from a structured rating scale (Conners, ADHD-RS-5, or similar). Functional impairment documented in at least two settings (school/work and home) for ADHD. Prior medication history with specific drug names, doses, trial durations, and reasons for discontinuation. For BED, a record of binge-eating frequency per DSM-5 moderate-severity threshold (8 or more episodes per month). A direct statement that Vyvanse (or generic lisdexamfetamine) is medically necessary because of specific clinical factors, not just "preferred by patient."

A 2019 survey of psychiatrists published in Psychiatric Services found that PA denials for stimulants were most often overturned on appeal when the prescriber submitted structured rating scale scores alongside narrative clinical notes, compared to narrative notes alone. Structured data cuts appeal time.